A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence Karim Matmat, Hélène Jamann, Amin Maazouzi, Kévin Bigaut, Michel Maitre, Jérôme De Seze, Ayikoé-Guy Mensah-Nyagan, Hélène Jeltsch-David Frontiers in Immunology, 2026 Objective Neuropsychiatric systemic lupus erythematosus (NPSLE) is among the most challenging manifestations of systemic lupus erythematosus (SLE), affecting the central and peripheral nervous systems with diverse symptoms. Despite its prevalence, the diagnosis and management of NPSLE remain complex due to the heterogeneity of clinical presentations and the lack of specific biomarkers. This study aims to synthesize data from case reports to better understand the clinical, biological, and imaging features of NPSLE. Methods A systematic review with integrated descriptive and exploratory quantitative analyses of 120 published case reports was conducted, integrating demographic, clinical, biological, and imaging data, as well as therapeutic approaches. Subgroup analyses stratified by age and sex were performed to identify descriptive patterns of presentation and outcomes. Results Age- and sex-related patterns were observed in disease presentations. Patients presenting at younger ages more frequently exhibited renal and cutaneous involvement, whereas those presenting in adulthood or at older ages more often displayed neurological and neuropsychiatric manifestations, including motor dysfunction, cognitive impairment, and mood disorders. Male patients exhibited higher rates of severe renal involvement, whereas neuropsychiatric symptoms were more frequently reported, particularly among female cases. Neuroimaging abnormalities were identified in over 80% of patients in whom imaging was performed, with common findings including white matter lesions, cortical atrophy, and focal gray matter involvement. Despite the widespread use of corticosteroids and immunosuppressants, treatment gaps persisted, particularly in the management of neuropsychiatric symptoms. Conclusion This review highlights the need for the development of biomarker-driven diagnostic tools and targeted therapies to address the unmet needs of NPSLE patients, while advances in imaging and biologics hold promises for improving patient outcomes. These findings should be interpreted as hypothesis-generating, given the descriptive nature of case-report–based evidence.
Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study Michaël Levraut, Mikael Cohen, Delphine Sterlin, Xavier Ayrignac, Kévin Bigaut, Hélène Zéphir, Jonathan Ciron, Jean-Philippe Camdessanché, Olivier Casez, Thibault Moreau, Elisabeth Maillart, Aude Maurousset, David Laplaud, Edith Bigot, Jean Pelletier, Eric Thouvenot, Christine Lebrun-Frénay Multiple Sclerosis Journal, 2026 Background: Limited evidence exists on how to use kappa free light chains (κFLCs) and oligoclonal bands (OCBs) in diagnosing intrathecal immunoglobulin synthesis (IgS). Objective: To compare different algorithms to define IgS. Methods: A retrospective analysis of the 2022 French cohort study was conducted. Patients were considered to have IgS if (1) the κFLC index was ⩾6.1, (2) OCB was positive, (3) the κFLC index was ⩾6.1 or OCB was positive, (4) the κFLC index was ⩾20 or OCB was positive, regardless of the κFLC index value, or (5) the κFLC index was ⩾20 or OCB was positive (with OCB tested only when the κFLC index was between 3.5 and 20). People with multiple sclerosis (MS) were compared with controls and with a subgroup of age- and sex-matched MS-mimicking disorders. Results: Of 1531 patients, 675 had MS and 856 were controls (133 MS mimics). Agreement between OCB and κFLC index (⩾6.1) was high (89%). All tested algorithms demonstrated high accuracy in separating groups. Using the sequential approach (5) achieves higher specificity and a significant reduction in OCB testing. Conclusion: Using a simple cut-off point of 6.1 for routine screening is accurate, but testing for OCB when the κFLC index is between 3.5 and 20 increases specificity and should be prospectively studied in challenging cases.
Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks Paulus S. Rommer, Wei Jiang, Jan P. Nolte, Takahisa Mikami, Jerome De Seze, Pedro Sánchez, Asaff Harel, Samir Alkabie, Kimihiko Kaneko, Philippe A. Bilodeau, Tatsuro Misu, Laurent Kremer, Kévin Bigaut, Frank Leypoldt, Orhan Aktas, Marius Ringelstein, Volker Siffrin, Lin-Jie Zhang, Hengri Cong, Mallory Lowe, Paula Barreras, Haiwen Chen, Amanda L. Piquet, Elias S. Sotirchos, Ryan Kammeyer, Jadyn Zook, Jeffrey L. Bennett, Thomas Berger, Kazuo Fujihara, Michael Levy, Fu-Dong Shi, Friedemann Paul Neurology Neuroimmunology and Neuroinflammation, 2026 BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease mainly driven by aquaporin-4 antibodies (AQP4-IgG). During an attack, AQP4-IgG activates the complement system, leading to astrocyte destruction, inflammation, neuronal damage, and thus devastating and often irreversible neurologic deficits. Terminal complement inhibitors such as eculizumab and ravulizumab effectively prevent relapses, yet their therapeutic potential in stopping ongoing complement-mediated injury during acute attacks remains insufficiently explored. METHODS: We conducted a multinational retrospective case series across NMOSD-specialized centers in 6 countries, analyzing 33 AQP4-IgG-positive patients (mean age: 48.1 years; 28 women) treated with component 5 (C5) inhibition during or shortly after acute relapse (mean 20.1 days from symptom onset; range 2-62). Eculizumab was used in 25 patients and ravulizumab in 8. Two additional patients were excluded because of delayed treatment initiation beyond 62 days. RESULTS: Lesion locations included myelitis (57.6%) and optic neuritis (30.3%). Expanded Disability Status Scale scores worsened from a pre-relapse median of 0 (interquartile range [IQR] 0-2) to a nadir of 6.5 (IQR 3.5-8), improving to 3.5 (IQR 3-6.5) at 1-3 months and 2.5 (IQR 2-6) at 6 months. All patients stabilized clinically; 20 continued C5 inhibition as attack-preventing therapy. Good, moderate, and poor/absent recovery were observed in 15, 11, and 7 patients, respectively. Earlier treatment was associated with better outcomes: treatment within 21 days yielded an odds ratio of 1.58 (95% CI 0.32-8.52) for good response. Plasma exchange was administered in 57.6% and was associated with higher overall response rates, but not with good response alone. DISCUSSION: These findings highlight the potential of complement inhibition as a treatment option for acute NMOSD attacks, particularly in patients with insufficient response to standard therapies. Given the absence of clinical worsening and the encouraging course observed in most of the patients, further investigation into the role of C5 inhibition in acute attack management is warranted. CLASSIFICATION OF EVIDENCE: This retrospective case series provides Class IV evidence that the C5 complement inhibitors eculizumab or ravulizumab may improve disability in patients with NMOSD when given during or shortly after acute relapse.
Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture Renaud Felten, Kevin Bigaut, Thomas Wirth, Laurent Kremer, Lucas Gauer, Cécile Arnold, Irène Ollivier, Julien Godet, Marc Scherlinger, Maxime Dubois, Eden Sebbag, Jerome De Sèze, Jacques-Eric Gottenberg BMC Medical Education, 2025 BACKGROUND: Lumbar puncture (LP) procedure can be challenging, creating stress for both patients and students. This study assesses the effectiveness of augmented reality (AR) and haptic feedback simulation training compared to traditional bedside teaching. METHOD: We conducted a prospective, single center, randomized controlled clinical trial with two parallel groups of medical students inexperienced in LP. Students were randomized to either the simulation group or the control group receiving traditional bedside teaching. Patients requiring LPs as part of their routine care were randomized. The primary outcome was LP success rate. Secondary outcomes included procedure duration, complication rates and patient and student perceptions. RESULTS: The study included 55 patients (AR group: n = 29; control group: n = 26). LP success rates were similar between groups (AR: 46.4%, control: 40.0%; p = 0.9). Median procedure duration was shorter in the AR group (138 s [IQR 37-454]) compared to the control group (695 s [IQR 15-900]), though not statistically significant (p = 0.67). Patient pain and anxiety scores did not differ significantly, but patients reported greater ease and higher satisfaction with simulator-trained students. Students in the AR group expressed greater comfort performing the procedure (7/10 vs. 6/10; p = 0.04). Complication rates were low and comparable across groups. CONCLUSION: Although augmented reality simulation training did not improve LP success rate, it improved the procedural speed and student ease without compromising technical performance. Patients preferred to be handled by simulator-trained students. These findings support the integration of AR technologies in medical training to improve efficiency and relational skills. CLINICALTRIALS: GOV: ID NCT05269238, Registration Date 2022-01-14.
An update on the evaluation of treatment switching criteria in multiple sclerosis Kevin Bigaut, Judicaelle Didierjean, Jerome de Seze Expert Review of Neurotherapeutics, 2025 INTRODUCTION Multiple sclerosis (MS) is a complex disorder driven by both inflammatory and neurodegenerative processes. While disease-modifying therapies (DMTs) have significantly improved prognosis, robust treatment switching criteria remain essential to balance efficacy and safety over the disease course. AREAS COVERED This review examines historical and current criteria for escalating DMTs from moderate- to high-efficacy therapies (HET). The authors summarize emerging clinical, imaging, and biological markers that inform decision-making and explore strategies for de-escalation, including DMT discontinuation and innovative approaches such as exit and bridge therapies. EXPERT OPINION Recent advances in MS management emphasize earlier initiation of HET and more stringent switching criteria. Although innovative monitoring tools - including clinical evaluations, imaging, biological markers, and patient-reported outcomes (PROs) - enhance disease assessment, they require further validation, standardization, and broader accessibility. Similarly, de-escalation criteria need additional research to optimize patient selection.
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study Elodie Berthet, Antoine Guillonnet, Caroline Houillier, Renata Ursu, Carole Soussain, Mehdi Touat, Antoine Gueguen, Benoît de Renzis, Kevin Bigaut, Guido Ahle, Pierre Durozard, Deborah Grosset‐Janin, Lucie Oberic, Antoine Bonnet, Anne‐Pascale Grandjean, Cécile Moluçon‐Chabrot, Khê Hoang‐Xuan, Hugues Chabriat, Stéphanie Guey Annals of Neurology, 2025 ObjectiveIntravascular lymphoma is a rare subtype of B‐cell lymphoma characterized by a clonal proliferation restricted to the lumen of small vessels. Over 50% of patients exhibit central nervous system (CNS) involvement, but diagnosis is often delayed due to the lack of distinctive features. We aimed to identify key phenotypic features for early diagnosis of intravascular lymphoma with CNS involvement through an in‐depth cohort study.MethodsWe built up a multicenter retrospective cohort of 17 patients recruited in collaboration with the French Expert Network for Oculo‐Cerebral Lymphomas (LOC network), and retrospectively analyzed data from medical records.ResultsIn this cohort, 15 of 17 (88%) patients developed focal neurological episodes, often fluctuating and/or recurrent, with a sudden onset in 68% of episodes, suggesting a vascular origin. Rapid cognitive deterioration occurred in 15 of 17 (88%) patients, psychiatric manifestations in 8 of 17 (47%), and “B signs” in 14 of 17 (82%). Brain MRI showed polymorphic FLAIR hyperintensities in 14 of 16 (87%) patients, and DWI‐positive lesions in 13 of 16 (81%) of patients, which accumulated over time and had unusual characteristics for ischemic lesions (progressive growth, persistent DWI‐hyperintensity over 1 month, surrounded by a wider FLAIR hyperintensity). Early‐onset inflammatory syndrome, and elevated lactate dehydrogenase (LDH) levels were observed in over 90% of cases. Mild and inconsistent meningitis contrasted with a nearly‐constant hyperproteinorachia. An increased interleukin 10/6 ratio over 0,7 was found in 4 of 7 (57%) patients, and skin biopsy led to a pathological diagnosis in 3 of 6 (50%) patients.InterpretationThe results of this study highlight “red flags” that could help accelerate the diagnosis of intravascular lymphoma involving the CNS. ANN NEUROL 2024
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment? Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, Xavier Ayrignac, Patrick Vermersch, Claudio Gobbi, Giulia Mallucci, Clarisse Carra-Dallière, Pierre Labauge, Kévin Bigaut, Laurent Kremer, Nicolas Collongues, Livia Lanotte, Eric Thouvenot, Christine Ernon, Dominique Dive Multiple Sclerosis Journal Experimental Translational and Clinical, 2025 Background Recent studies support the need for early and intensive disease-modifying treatment (DMT) for patients with multiple sclerosis (PWMS). Abrupt DMT withdrawal may risk disease reactivation. Recent studies showed that MS disease activity was not rare after DMT withdrawal for PWMS aged >45/55 y. Immune reconstitution therapy (IRT) with cladribine tablets (CladT), may be an option for older PWMS who wish to stop DMT. Objective We retrospectively analysed PWMS aged >45 y who initiated CladT in 6 MS centers in Europe. Results One hundred and twenty nine PWMS (95 women/34 men, mean age 55.0 +/-7.5y initiated CladT; 83 (64.3%) previously received platform DMT, 35 (27.2%) previously received high efficacy DMT and 11 (8.5%) received CladT as a 1 st DMT due to a late onset of MS or to a delayed therapy decision. Mean follow-up was 2.4 y (1–5) on CladT. Only three patient experienced 4 relapses. The first one had 2 relapses after switching from fingolimod with a 2-month interval between treatments. The 2 remaining were naïve patients that had a relapse between the 2 courses of CladT. Conclusion Last/exit therapy with CladT seems to avoid MS disease reactivation in older PWMS and may be an interesting alternative solution to continue immunosuppression/immunomodulation.
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis Antoine Gavoille, Fabien Rollot, Romain Casey, Anne Kerbrat, Emmanuelle Le Page, Kevin Bigaut, Guillaume Mathey, Laure Michel, Jonathan Ciron, Aurelie Ruet, Elisabeth Maillart, Pierre Labauge, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Eric Berger, Bruno Stankoff, Pierre Clavelou, Eric Thouvenot, Olivier Heinzlef, Jean Pelletier, Abdullatif Al-Khedr, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean-Philippe Camdessanché, Inès Doghri, Solène Moulin, Haifa Ben-Nasr, Céline Labeyrie, Karolina Hankiewicz, Jean-Philippe Neau, Corinne Pottier, Chantal Nifle, Eric Manchon, Bertrand Lapergue, Sandrine Wiertlewski, Jérôme De Sèze, Sandra Vukusic, David Axel Laplaud, , François Cotton, Pascal Douek, Francis Guillemin, Alexandre Pachot, Javier Olaiz, Claire Rigaud-Bully, Romain Marignier, Guillaume Mathey, Anne Kerbrat, Damien Biotti, Jean-Christophe Ouallet, Nicolas Collongues, Olivier Outteryck, Xavier Moisset, Nathalie Derache, Mikaël Cohen, Agnès Fromont, Sandrine Wiertlewsky, Matthieu Bereau, Bertrand Audoin, Claire Giannesini, Caroline Bensa, Giovanni Castelnovo, Ombeline Fagniez, Benjamin Hebant, Mathieu Vaillant, Séverine Jeanin, Alain Créange, Jean-Michel Vallat, Philippe Convers, Stéphane Beltran, Céline Labeyrie, Carole Henry, Marie Camuzeaux, Maryline Delattre, Laura Trotta, Catherine Girod, Amandine Ostermann-Ziegler, Damien Le Port, Noellie Freitas, Carole Berthe, Katy-Kim Lataste, Karima Zehrouni, Frédéric Pinna, Julie Petit, Sadou Safa Diallo, Karine Droulon, Céline Callier, Alexia Protin, Melinda Moyon, Chrystelle Cappe, Emilie Dumont, Hanane Agherbi, Marie Blanchere, Marie-Pierre Ranjeva, Amandine Da Veiga, Maty Diop Kane, Christine Vimont, Marjory Cayol, Safiyatou Balde, Daisy Rousseau, Karine Ferraud, Géraldine Meunier, Elise Varnier, Edwige Lescieux, Halima Bourenane, Stéphanie Cossec, Emilie Rabois, Lynda Benammar, Anaïs Beulaygue JAMA Neurology, 2024
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society Nicolas Collongues, Françoise Durand-Dubief, Christine Lebrun-Frenay, Bertrand Audoin, Xavier Ayrignac, Caroline Bensa, Kévin Bigaut, Bertrand Bourre, Clarisse Carra-Dallière, Jonathan Ciron, Gilles Defer, Arnaud Kwiatkowski, Emmanuelle Leray, Elisabeth Maillart, Romain Marignier, Guillaume Mathey, Nathalie Morel, Eric Thouvenot, Hélène Zéphir, Julie Boucher, Clémence Boutière, Pierre Branger, Angélique Da Silva, Sarah Demortière, Maxime Guillaume, Benjamin Hebant, Edouard Januel, Anne Kerbrat, Eric Manchon, Xavier Moisset, Alexis Montcuquet, Chloé Pierret, Julie Pique, Julien Poupart, Chloé Prunis, Thomas Roux, Perrine Schmitt, Géraldine Androdias, Mikael Cohen Multiple Sclerosis Journal, 2024
High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Emmanuelle Le Page, Laure Michel, Gilles Edan, Jérome de Seze, Laurent Kremer, Kevin Bigaut, Sandra Vukusic, Guillaume Mathey, Jonathan Ciron, Aurélie Ruet, Elisabeth Maillart, Pierre Labauge, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, David Axel Laplaud, Eric Berger, Bruno Stankoff, Pierre Clavelou, Eric Thouvenot, Olivier Heinzlef, Jean Pelletier, Abdullatif Al-Khedr, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean-Philippe Camdessanché, Ines Doghri, Solène Moulin, Haifa Ben-Nasr, Céline Labeyrie, Karolina Hankiewicz, Jean-Philippe Neau, Corinne Pottier, Chantal Nifle, Nicolas Collongues, Anne Kerbrat, François Cotton, Pascal Douek, Francis Guillememin, Alexandre Pachot, Javier Olaiz, Claire Rigaud-Bully, Romain Marignier, Marc Debouverie, Catherine Lubetzki, Mikaël Cohen, Agnès Fromont, Sandrine Wiertlewsky, Bertrand Audoin, Claire Giannesini, Olivier Gout, Alexis Montcuquet, Serge Bakchine, Aude Maurousset, Nicolas Maubeuge, and JAMA Neurology, 2024
Clinical features and maternal and fetal outcomes in women with Guillain-Barré syndrome in pregnancy Nolwenn Krief, René Gabriel, Cécile Cauquil, David Adams, Guillaume Fargeot, Thierry Maisonobe, David Osman, Matthieu Schmidt, Jean-Baptiste Chanson, Kevin Bigaut, Guilhem Sole, Céline Tard, Guillaume Nicolas, Yann Pereon, Karine Aure, Emmeline Lagrange, Mathilde Lefilliatre, Marc-Antoine Labeyrie, Andoni Echaniz-Laguna Journal of Neurology, 2023
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer Neurology and Therapy, 2023
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study Michael Levraut, Sabine Laurent-Chabalier, Xavier Ayrignac, Kévin Bigaut, Manon Rival, Sanae Squalli, Hélène Zéphir, Tifanie Alberto, Jean-David Pekar, Jonathan Ciron, Damien Biotti, Bénédicte Puissant-Lubrano, Jean-Philippe Camdessanché, Yannick Tholance, Olivier Casez, Bertrand Toussaint, Jeanne Marion, Thibault Moreau, Daniela Lakomy, Audrey Thomasset, Elisabeth Maillart, Delphine Sterlin, Aude Maurousset, Auriane Rocher, David Axel Laplaud, Edith Bigot-Corbel, Pierre-Olivier Bertho, Jean Pelletier, Joseph Boucraut, Pierre Labauge, Thierry Vincent, Jérôme De Sèze, Isabelle Jahn, Barbara Seitz-Polski, Eric Thouvenot, Christine Lebrun-Frenay Neurology Neuroimmunology and Neuroinflammation, 2023
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society Sandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, Elisabeth Maillart, Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, Bertrand Bourre, David Laplaud, Géraldine Androdias, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Mikael Cohen, Elodie Daval, Romain Deschamps, Cécile Donze, Anne-Laure Dubessy, Cécile Dulau, Françoise Durand-Dubief, Maxime Guillaume, Benjamin Hebant, Laurent Kremer, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Julie Pique, Thomas Roux, Romain Marignier, Christine Lebrun-Frenay; Multiple Sclerosis Journal, 2023
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society Sandra Vukusic, Romain Marignier, Jonathan Ciron, Bertrand Bourre, Mikael Cohen, Romain Deschamps, Maxime Guillaume, Laurent Kremer, Julie Pique, Clarisse Carra-Dalliere, Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, David Laplaud, Géraldine Androdias, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Elodie Daval, Cécile Donze, Anne-Laure Dubessy, Cécile Dulau, Françoise Durand-Dubief, Benjamin Hebant, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Thomas Roux, Elisabeth Maillart, Christine Lebrun-Frenay Multiple Sclerosis Journal, 2023
Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study T. Bogdan, T. Wirth, A. Iosif, A. Schalk, S. Montaut, C. Bonnard, G. Carre, O. Lagha-Boukbiza, C. Reschwein, E. Albugues, S. Demuth, H. Landsberger, M. Einsiedler, T. Parratte, A. Nguyen, F. Lamy, H. Durand, P. Fahrer, P. Voulleminot, K. Bigaut, J. B. Chanson, G. Nicolas, J. Chelly, C. Cazeneuve, M. Koenig, C. Bund, I. J. Namer, S. Kremer, N. Calmels, C. Tranchant, M. Anheim Journal of Neurology, 2022
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica Edouard Januel, Jérôme De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, Xavier Moisset, Caroline Bensa, Adil Maarouf, Jean Pelletier, Sandra Vukusic, Bertrand Audoin, Céline Louapre, Stéphane Beltran, Eric Berger, Kevin Bigaut, Nathalie Derache, Salimata Gassama, Olivier Heinzlef, Laurent Kremer, Philippe Kerschen, Aude Maurousset, Vito A G Ricigliano, Pierre-Yves Garcia, Pierre Labauge Multiple Sclerosis Journal, 2022
Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis Bhagteshwar Singh, Suzannah Lant, Sofia Cividini, Jonathan W. S. Cattrall, Lynsey C. Goodwin, Laura Benjamin, Benedict D. Michael, Ayaz Khawaja, Aline de Moura Brasil Matos, Walid Alkeridy, Andrea Pilotto, Durjoy Lahiri, Rebecca Rawlinson, Sithembinkosi Mhlanga, Evelyn C. Lopez, Brendan F. Sargent, Anushri Somasundaran, Arina Tamborska, Glynn Webb, Komal Younas, Yaqub Al Sami, Heavenna Babu, Tristan Banks, Francesco Cavallieri, Matthew Cohen, Emma Davies, Shalley Dhar, Anna Fajardo Modol, Hamzah Farooq, Jeffrey Harte, Samuel Hey, Albert Joseph, Dileep Karthikappallil, Daniel Kassahun, Gareth Lipunga, Rachel Mason, Thomas Minton, Gabrielle Mond, Joseph Poxon, Sophie Rabas, Germander Soothill, Marialuisa Zedde, Konstantin Yenkoyan, Bruce Brew, Erika Contini, Lucette Cysique, Xin Zhang, Pietro Maggi, Vincent van Pesch, Jérome Lechien, Sven Saussez, Alex Heyse, Maria Lúcia Brito Ferreira, Cristiane N. Soares, Isabel Elicer, Laura Eugenín-von Bernhardi, Waleng Ñancupil Reyes, Rong Yin, Mohammed A. Azab, Foad Abd-Allah, Ahmed Elkady, Simon Escalard, Jean-Christophe Corvol, Cécile Delorme, Pierre Tattevin, Kévin Bigaut, Norbert Lorenz, Daniel Hornuss, Jonas Hosp, Siegbert Rieg, Dirk Wagner, Benjamin Knier, Paul Lingor, Andrea Sylvia Winkler, Athena Sharifi-Razavi, Shima T. Moein, SeyedAhmad SeyedAlinaghi, Saeidreza JamaliMoghadamSiahkali, Mauro Morassi, Alessandro Padovani, Marcello Giunta, Ilenia Libri, Simone Beretta, Sabrina Ravaglia, Matteo Foschi, Paolo Calabresi, Guido Primiano, Serenella Servidei, Nicola Biagio Mercuri, Claudio Liguori, Mariangela Pierantozzi, Loredana Sarmati, Federica Boso, Silvia Garazzino, Sara Mariotto, Kimani N. Patrick, Oana Costache, Alexander Pincherle, Frederikus A. Klok, Roger Meza, Verónica Cabreira, Sofia R. Valdoleiros, Vanessa Oliveira, Igor Kaimovsky, Alla Guekht, Jasmine Koh, Eva Fernández Díaz, José María Barrios-López, Cristina Guijarro-Castro, Álvaro Beltrán-Corbellini, Javier Martínez-Poles, Alba María Diezma-Martín, Maria Isabel Morales-Casado, Sergio García García, Gautier Breville, Matteo Coen, Marjolaine Uginet, Raphaël Bernard-Valnet, Renaud Du Pasquier, Yildiz Kaya, Loay H. Abdelnour, Claire Rice, Hamish Morrison, Sylviane Defres, Saif Huda, Noelle Enright, Jane Hassell, Lucio D’Anna, Matthew Benger, Laszlo Sztriha, Eamon Raith, Krishna Chinthapalli, Ross Nortley, Ross Paterson, Arvind Chandratheva, David J. Werring, Samir Dervisevic, Kirsty Harkness, Ashwin Pinto, Dinesh Jillella, Scott Beach, Kulothungan Gunasekaran, Ivan Rocha Ferreira Da Silva, Krishna Nalleballe, Jonathan Santoro, Tyler Scullen, Lora Kahn, Carla Y. Kim, Kiran T. Thakur, Rajan Jain, Thirugnanam Umapathi, Timothy R. Nicholson, James J. Sejvar, Eva Maria Hodel, Catrin Tudur Smith, Tom Solomon, and Plos One, 2022
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS Mikael Cohen, Lydiane Mondot, Florence Bucciarelli, Béatrice Pignolet, David-Axel Laplaud, Sandrine Wiertlewski, Bruno Brochet, Aurélie Ruet, Gilles Defer, Nathalie Derache, Patrick Vermersch, Hélène Zephir, Marc Debouverie, Guillaume Mathey, Eric Berger, Chrystelle Cappé, Pierre Labauge, Clarisse Carra, Jérôme De Seze, Kevin Bigaut, David Brassat, Christine Lebrun-Frenay Multiple Sclerosis Journal, 2021
Troubles de la marche d’installation progressive chez un homme de 37 ans D Ricard, L Lamarque, K Bigaut, A Fattori, F Sellal Pratique Neurologique-FMC , 2026 2026
High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies A Gervais, A Marchal, A Maillard, T Le Voyer, J Rosain, Q Philipot, ... Medrxiv , 2026 2026
Impact des chimiothérapies anticancéreuses sur le risque de poussées de sclérose en plaques G Jouvenot, S Lopes, W Storck, J De Sèze, L Kremer, K Bigaut, ... Revue Neurologique 182, S146 , 2026 2026
État des lieux de la prise en charge de la sclérose en plaques en France en 2024–2025: une enquête nationale C Carriat, K Bigaut, J De Seze Revue Neurologique 182, S157 , 2026 2026
Évolution cognitive et thymique sous traitements de fond et lien avec la fatigue et la qualité de vie L Pfaff, T Labaume, C Berthe, MC Fleury, N Collongues, L Kremer, ... Revue Neurologique 182, S160-S161 , 2026 2026
Évaluation de l’efficacité des inhibiteurs du facteur de nécrose tumorale (anti-TNF) dans la neurosarcoïdose: une étude monocentrique rétrospective T Flamand, K Bigaut, C Tranchant, J De Seze, L Kremer, N Collongues Revue Neurologique 182, S132 , 2026 2026
A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence K Matmat, H Jamann, A Maazouzi, K Bigaut, M Maitre, J De Seze, ... Frontiers in Immunology 17, 1768131 , 2026 2026
Complement inhibition for acute neuromyelitis optica spectrum disorder attacks: Insights from an international case series PS Rommer, W Jiang, JP Nolte, T Mikami, J De Seze, P Sánchez, A Harel, ... Neurology: Neuroimmunology & Neuroinflammation 13 (2), e200548 , 2026 2026 Citations: 2
Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study M Levraut, M Cohen, D Sterlin, X Ayrignac, K Bigaut, H Zéphir, J Ciron, ... Multiple Sclerosis Journal, 13524585261442020 , 2025 2025
Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials A Gavoille, S Demuth, M Nourredine, I Faddeenkov, F Rollot, R Casey, ... medRxiv, 2025.10. 10.25337738 , 2025 2025 Citations: 1
Complement inhibition in acute NMOSD attacks: Insights from a multicentric case series P Rommer, W Jiang, J Nolte, T Mikami, J De Seze, P Sanchez-Lopez, ... MULTIPLE SCLEROSIS JOURNAL 31 (3), 145-146 , 2025 2025
Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture R Felten, K Bigaut, T Wirth, L Kremer, L Gauer, C Arnold, I Ollivier, J Godet, ... BMC Medical Education 25 (1), 1231 , 2025 2025 Citations: 7
Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study J Didierjean, L Kremer, L Lanotte, S Courtois, G Carré, N Collongues, ... Multiple Sclerosis and Related Disorders, 106690 , 2025 2025 Citations: 1
An update on the evaluation of treatment switching criteria in multiple sclerosis K Bigaut, J Didierjean, J de Seze Expert Review of Neurotherapeutics 25 (8), 911-928 , 2025 2025 Citations: 1
Évaluation de l’efficacité du bloc sphénopalatin comme alternative au blood-patch épidural en traitement du syndrome post-ponction lombaire: une étude monocentrique A Daudon, S Koessler, L Kremer, K Bigaut Revue Neurologique 181, S17-S18 , 2025 2025
Pédagogie 2.0: réalité augmentée pour optimiser l’apprentissage des ponctions lombaires K Bigaut, JE Gottenberg, T Wirth, I Ollivier, L Gauer, J De Sèze, R Felten Revue Neurologique 181, S117 , 2025 2025
Vaincre la neurophobie par le jeu? Le Neuromancien, un outil pour l’apprentissage du raisonnement neurologique K Bigaut, T Wirth Revue Neurologique 181, S116 , 2025 2025
SUNCT onset following ophthalmic-distribution zoster: Description of a case and review of the literature A Storck, M Fleury, G Tacchi, G Maffon, L Kremer, K Bigaut Revue neurologique 181 (3), 232-235 , 2025 2025
Unveiling the clinical and imaging signatures of intravascular lymphoma of the central nervous system: A multicentric cohort study E Berthet, A Guillonnet, C Houillier, R Ursu, C Soussain, M Touat, ... Annals of Neurology 97 (3), 435-448 , 2025 2025 Citations: 9
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment? J de Seze, C Zecca, G Castelnovo, X Ayrignac, P Vermersch, C Gobbi, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 11 (1 … , 2025 2025 Citations: 7
MOST CITED SCHOLAR PUBLICATIONS
Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis C Louapre, N Collongues, B Stankoff, C Giannesini, C Papeix, C Bensa, ... JAMA neurology 77 (9), 1079-1088 , 2020 2020 Citations: 522
Guillain-Barré syndrome related to SARS-CoV-2 infection K Bigaut, M Mallaret, S Baloglu, B Nemoz, P Morand, F Baicry, A Godon, ... Neurology: Neuroimmunology & Neuroinflammation 7 (5), e785 , 2020 2020 Citations: 144
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France MP Sormani, M Salvetti, P Labauge, I Schiavetti, H Zephir, L Carmisciano, ... Annals of Clinical and Translational Neurology 8 (8), 1738-1744 , 2021 2021 Citations: 132
Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: a large multicenter cohort study M Levraut, S Laurent-Chabalier, X Ayrignac, K Bigaut, M Rival, S Squalli, ... Neurology: Neuroimmunology & Neuroinflammation 10 (1), e200049 , 2022 2022 Citations: 77
A rise in cases of nitrous oxide abuse: neurological complications and biological findings M Einsiedler, P Voulleminot, S Demuth, P Kalaaji, T Bogdan, L Gauer, ... Journal of Neurology 269 (2), 577-582 , 2022 2022 Citations: 49
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society S Vukusic, C Carra-Dalliere, J Ciron, E Maillart, L Michel, E Leray, ... Multiple Sclerosis Journal 29 (1), 11-36 , 2023 2023 Citations: 48
Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis B Singh, S Lant, S Cividini, JWS Cattrall, LC Goodwin, L Benjamin, ... PLoS One 17 (6), e0263595 , 2022 2022 Citations: 47
High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS G Jouvenot, G Courbon, M Lefort, F Rollot, R Casey, E Le Page, L Michel, ... JAMA neurology 81 (5), 490-498 , 2024 2024 Citations: 44
Ocrelizumab for the treatment of multiple sclerosis K Bigaut, J De Seze, N Collongues Expert review of neurotherapeutics 19 (2), 97-108 , 2019 2019 Citations: 43
Impact of disease-modifying treatments of multiple sclerosis on anti–SARS-CoV-2 antibodies: an observational study K Bigaut, L Kremer, T Fabacher, L Lanotte, MC Fleury, N Collongues, ... Neurology: Neuroimmunology & Neuroinflammation 8 (5), e1055 , 2021 2021 Citations: 41
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society S Vukusic, R Marignier, J Ciron, B Bourre, M Cohen, R Deschamps, ... Multiple Sclerosis Journal 29 (1), 37-51 , 2023 2023 Citations: 36
Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection K Bigaut, L Kremer, M Fleury, L Lanotte, N Collongues, J de Sèze Revue neurologique 177 (10), 1237-1240 , 2021 2021 Citations: 36
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP) K Bigaut, M Cohen, F Durand-Dubief, E Maillart, E Planque, H Zephir, ... Multiple sclerosis and related disorders 53, 103076 , 2021 2021 Citations: 34
Severe early-onset impulsive compulsive behavior and psychosis in PLA2G6-related juvenile Parkinson's disease T Wirth, S Weibel, S Montaut, K Bigaut, G Rudolf, J Chelly, C Tranchant, ... Parkinsonism & Related Disorders 41, 127-129 , 2017 2017 Citations: 33
The translatability of multiple sclerosis animal models for biomarkers discovery and their clinical use D Birmpili, I Charmarke Askar, K Bigaut, D Bagnard International journal of molecular sciences 23 (19), 11532 , 2022 2022 Citations: 31
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study K Bigaut, L Kremer, T Fabacher, G Ahle, M Goudot, M Fleury, C Gaultier, ... Journal of Neurology 269 (6), 3295-3300 , 2022 2022 Citations: 30
An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies S Brun, N Schall, SR Bonam, K Bigaut, AG Mensah-Nyagan, J de Sèze, ... Journal of Autoimmunity 92, 114-125 , 2018 2018 Citations: 30
Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis A Gavoille, F Rollot, R Casey, A Kerbrat, E Le Page, K Bigaut, G Mathey, ... JAMA neurology 81 (8), 814-823 , 2024 2024 Citations: 26
Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study T Bogdan, T Wirth, A Iosif, A Schalk, S Montaut, C Bonnard, G Carre, ... Journal of Neurology 269 (12), 6354-6365 , 2022 2022 Citations: 26
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica E Januel, J De Seze, P Vermersch, E Maillart, B Bourre, J Pique, ... Multiple Sclerosis Journal 28 (7), 1155-1159 , 2022 2022 Citations: 25
